Improving patient access!  |  SOTYKTU is covered for ~80% of commercially insured patients with no branded step requirements||

WHEN TOPICALS AREN'T ENOUGH, START WITH SOTYKTU

For your moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy1

Actor portrayal of SOTYKTU® patient with plaque psoriasis
Spine

SUPERIOR EFFICACY

UP TO 2x THE EFFICACY
VS APREMILAST1*

Safety Badge

SAFETY
PROFILE

THROUGH 5 YEARS
IN CLINICAL TRIALS2,3‡

SOTYKTU® has once-daily dosing

SIMPLE

ONCE-DAILY
DOSING

5 year data

DURABLE

RESPONSE RATES
THROUGH 5 YEARS

* POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis. See additional study design details.1
Co-primary endpoints: percentage of patients achieving PASI 75 at Week 16 vs placebo and percentage of patients achieving sPGA 0/1 vs placebo at Week 16. The results were achieved for PASI 75 (POETYK PSO-1: 58% vs 13%; POETYK PSO-2: 53% vs 9%); and sPGA 0/1 (POETYK PSO-1: 54% vs 7%; POETYK PSO-2: 50% vs 9%). Statistical significance was achieved for secondary endpoint PASI 90 vs apremilast at Week 24 (POETYK PSO-1: 42% vs 22%; POETYK PSO-2: 32% vs 20%).1
Patients had varying lengths of treatment exposure. 2,3
§ Evaluate patients for active and latent tuberculosis prior to initiating treatment. Update immunizations according to current immunization guidelines. Monitor for laboratory abnormalities. SOTYKTU is not recommended for patients with severe hepatic impairment. Tablets should be taken whole.1
In POETYK PSO-LTE, PASI 75 response rates in patients treated with continuous SOTYKTU (n=485) were 72% at Week 52 and 67% at Week 256.
Data derived from a post hoc sub-analysis and was analyzed descriptively.3 In open-label LTEs, patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may raise the proportion of responders in the overall population.
|| Because formularies change and many payers offer more than one formulary, please check directly with the payer to confirm requirements and status for individual patients. Coverage and benefits are subject to change without notice. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item. Bristol Myers Squibb does not endorse any individual health plans.

SOTYKTU tablet is not actual size. Shown for illustrative purposes only.

LTE=long-term extension; PASI=Psoriasis Area and Severity Index; PASI 75=≥75% improvement from baseline in PASI; sPGA 0/1=static Physician’s Global Assessment, patients achieving clear (0) or almost clear (1) skin.

Hands and Heart

SOTYKTU RESOURCES
Check here for information about patient support, program details, enrollment information, and downloadable resources.

QUICK POLL

Check Mark
Loading...
References:
  1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  2. Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024;190:668-679. doi:10.1093/bjd/ljae014
  3. Armstrong AW, Warren RB, Strober B, et al. Deucravacitinib in moderate to severe plaque psoriasis: 5-year, long-term safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at: Winter Clinical Dermatology Conference; February 14-19, 2025; Waikoloa, Hawaii.


  Bristol Myers Squibb® Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
This site is intended for U.S. Healthcare Professionals only.
Otezla is a registered trademark of Amgen Inc.
© 2025 Bristol-Myers Squibb Company.

1787-US-2500022 09/25

Legal Notice    Privacy Policy    Your Privacy Choices Privacy Link    Sitemap